Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$79.53 USD
-0.15 (-0.19%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $79.56 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.53 USD
-0.15 (-0.19%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $79.56 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
Doctor Reddy's (RDY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Doctor Reddy's (RDY) closed at $53.25, marking a +0.02% move from the previous day.
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
New Strong Buy Stocks for November 17th
by Zacks Equity Research
PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.
Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Sundeep Ganoria
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
by Zacks Equity Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
New Strong Sell Stocks for May 20th
by Zacks Equity Research
Teaser: CBAN, CHUY, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2022.
New Strong Sell Stocks for May 18th
by Zacks Equity Research
ALX, CBAN, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2022.
New Strong Sell Stocks for May 12th
by Zacks Equity Research
CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
New Strong Sell Stocks for November 22nd
by Zacks Equity Research
RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.
New Strong Sell Stocks for November 4th
by Zacks Equity Research
ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.